Drug intelligence / Profile preview

SO-006

Development stage: Preclinical
Lead developer: SOICUM
Modality: Small Molecules

Overview

SO-006 is a small molecule drug candidate being developed by SOCIUM (formerly SOICUM) through a drug repositioning strategy. As a repositioned asset, SO-006 is an existing approved drug being investigated for new therapeutic applications, primarily in pancreatic cancer and Parkinson's disease. In the context of pancreatic cancer, SO-006 is intended to improve treatment efficacy by overcoming drug resistance mechanisms. The program is currently in the preclinical stage of development. SOCIUM is also developing a related new compound, SO-006D, for similar oncology indications. There is some conflict in historical pipeline data regarding the specific indication associated with the SO-006 code, with earlier sources linking it to Parkinson's disease and more recent 2026 pipeline updates focusing on its role in pancreatic cancer resistance.

Beyond the preview

Go deeper on SO-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SO-006.

Explore the full profile